Cargando…

Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications

Malignant pleural mesothelioma (MPM) tumors are remarkably aggressive and most patients only survive for 5–12 months; irrespective of stage; after primary symptoms appear. Compounding matters is that MPM remains unresponsive to conventional standards of care; including radiation and chemotherapy. Cu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tolani, Bhairavi, Acevedo, Luis A., Hoang, Ngoc T., He, Biao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796186/ https://www.ncbi.nlm.nih.gov/pubmed/29342862 http://dx.doi.org/10.3390/ijms19010238

Ejemplares similares

A review of soft-tissue sarcomas: translation of biological advances into treatment measures
por: Hoang, Ngoc T, et al.
Publicado: (2018)

Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog
por: Tolani, Bhairavi, et al.
Publicado: (2018)

Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring
por: Chang, Yi, et al.
Publicado: (2017)

Malignant Pleural Mesothelioma (MPM) Presenting as Hydropneumothorax
por: Kuramochi, Masami, et al.
Publicado: (2023)

Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM)
por: Ferguson, Robert, et al.
Publicado: (2019)

Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer
por: Giroux Leprieur, Etienne, et al.
Publicado: (2017)

Simplified approach to ICU severity scoring with MPM and EUROSCORE
por: Reeves, JH, et al.
Publicado: (2010)

Preliminary update of the Mortality Probability Model (MPM0)
por: Higgins, T, et al.
Publicado: (2005)

A Novel Panel of Serum Biomarkers for MPM Diagnosis
por: Bonotti, A., et al.
Publicado: (2017)

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2021)

Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes a Prognostic Signature
por: Cioce, Mario, et al.
Publicado: (2021)

MTA1 promotes metastasis of MPM via suppression of E-cadherin
por: Xu, Caihua, et al.
Publicado: (2015)

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
por: Gounant, Valérie, et al.
Publicado: (2021)

A deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma
por: Li, Wei, et al.
Publicado: (2023)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017)

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
por: Pagano, Maria, et al.
Publicado: (2020)

At least two kinases phosphorylate the MPM-2 epitope during Xenopus oocyte maturation
Publicado: (1993)

Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
por: Wright, Casey M., et al.
Publicado: (2013)

DeepMPM: a mortality risk prediction model using longitudinal EHR data
por: Yang, Fan, et al.
Publicado: (2022)

KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM)
por: Lorenzini, Eugenia, et al.
Publicado: (2022)

Mortality probability model II (MPM(0–72)) in 1667 patients with acute cardiovascular disorders
por: Janssens, U, et al.
Publicado: (2002)

Predicting Mortality in Low-Income Country ICUs: The Rwanda Mortality Probability Model (R-MPM)
por: Riviello, Elisabeth D., et al.
Publicado: (2016)

A novel mitochondrial micropeptide MPM enhances mitochondrial respiratory activity and promotes myogenic differentiation
por: Lin, Yi-Fang, et al.
Publicado: (2019)

External Validation Of The Surgical Mortality Probability Model (S-MPM) In Patients Undergoing Non-Cardiac Surgery
por: Kazimierczak, Sebastian, et al.
Publicado: (2019)

The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
por: Yuen, Man Lee, et al.
Publicado: (2021)

Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells
por: Hegedüs, Luca, et al.
Publicado: (2022)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
por: Yang, Liu, et al.
Publicado: (2023)

Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
por: Gopalakrishnan, Ramakrishnan, et al.
Publicado: (2015)

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
por: Tolani, Bhairavi, et al.
Publicado: (2013)

Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing
por: Laure, Alexander, et al.
Publicado: (2023)

Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients
por: Cedres, Susana, et al.
Publicado: (2023)

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
por: Mark, M., et al.
Publicado: (2022)

Multisite phosphorylation of Pin1-associated mitotic phosphoproteins revealed by monoclonal antibodies MPM-2 and CC-3
por: Albert, Alexandra L, et al.
Publicado: (2004)

Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM)
por: Karimian-Jazi, Kianush, et al.
Publicado: (2020)

MA04.07 Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection
por: Cedres, S., et al.
Publicado: (2021)

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2020)

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
por: Cedrés, Susana, et al.
Publicado: (2015)

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
por: Mendoza, Tito R., et al.
Publicado: (2019)

External validation of SAPS 3 and MPM(0)-III scores in 48,816 patients from 72 Brazilian ICUs
por: Moralez, Giulliana Martines, et al.
Publicado: (2017)

The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
por: Rozitis, Eric, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3106pj9kqjhe24thrdd9o8vgf5